首页> 外国专利> USE OF PIPAMPERONE AND AN SNDRI, SNRI OR SSRI FOR THE TREATMENT OF STATE AND ANXIETY DISORDERS.

USE OF PIPAMPERONE AND AN SNDRI, SNRI OR SSRI FOR THE TREATMENT OF STATE AND ANXIETY DISORDERS.

机译:使用皮帕酮和SNDRI,SNRI或SSRI治疗状态和焦虑症。

摘要

Use of pipamperone or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of a mood disorder or an anxiety disorder, wherein said pipamperone or a pharmaceutically acceptable salt is to be administered to a patient in a daily dose in the range between 5 and 15 mg of the active ingredient, and where a second compound is to be administered simultaneously, separately or sequentially with respect to said pipamperone to increase the therapeutic effect of said second compound, said second compound being selected from the group consisting of: a selective serotonin, noradrenaline, and dopamine reuptake inhibitor (SNDRI), a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and a selective serotonin reuptake inhibitor (SSRI).
机译:匹帕酮或其药学上可接受的盐在制备用于治疗心境障碍或焦虑症的药物中的用途,其中所述匹帕酮或其药学上可接受的盐以每天剂量范围在5和15 mg的活性成分,以及要同时,分别或依次给予所述吡哌酮以提高所述第二化合物的治疗效果的第二化合物,所述第二化合物选自:选择性5-羟色胺,去甲肾上腺素和多巴胺再摄取抑制剂(SNDRI),选择性5-羟色胺和去甲肾上腺素再摄取抑制剂(SNRI)和选择性5-羟色胺再摄取抑制剂(SSRI)。

著录项

  • 公开/公告号ES2323269T3

    专利类型

  • 公开/公告日2009-07-10

    原文格式PDF

  • 申请/专利权人 PHARMANEUROBOOST N.V.;

    申请/专利号ES20040025035T

  • 发明设计人 BUNTINX ERIK;

    申请日2004-10-21

  • 分类号A61K31/343;A61K45;A61K31;A61K31/4545;A61P25;A61P25/04;A61P25/14;A61P25/16;A61P25/20;A61P25/22;A61P25/24;A61P25/28;A61P43;G01N33/48;

  • 国家 ES

  • 入库时间 2022-08-21 19:23:44

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号